Literature DB >> 27638651

Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Christoph Langenstein1, Diana Schork2, Klaus Badenhoop2, Eva Herrmann3.   

Abstract

PROBLEM: Graves' disease (GD) is an important and prevalent thyroid autoimmune disorder. Standard therapy for GD consists of antithyroid drugs (ATD) with treatment periods of around 12 months but relapse is frequent. Since predictors for relapse are difficult to identify the individual decision making for optimal treatment is often arbitrary.
METHODS: After reviewing the literature on this topic we summarize important factors involved in GD and with respect to their potential for relapse prediction from markers before and after treatment. This information was used to design a mathematical model integrating thyroid hormone parameters, thyroid size, antibody titers and a complex algorithm encompassing genetic predisposition, environmental exposures and current immune activity in order to arrive at a prognostic index for relapse risk after treatment.
CONCLUSION: In the search for a tool to analyze and predict relapse in GD mathematical modeling is a promising approach. In analogy to mathematical modeling approaches in other diseases such as viral infections, we developed a differential equation model on the basis of published clinical trials in patients with GD. Although our model needs further evaluation to be applicable in a clinical context, it provides a perspective for an important contribution to a final statistical prediction model.

Entities:  

Keywords:  Graves’ disease; Hyperthyroidism; Mathematical modeling; Relapse

Mesh:

Year:  2016        PMID: 27638651     DOI: 10.1007/s11154-016-9386-8

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  74 in total

1.  Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts.

Authors:  T H Brix; K O Kyvik; K Christensen; L Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 2.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

3.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors:  P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal:  Thyroid       Date:  1997-06       Impact factor: 6.568

4.  A 2013 European survey of clinical practice patterns in the management of Graves' disease.

Authors:  L Bartalena; H B Burch; K D Burman; G J Kahaly
Journal:  Clin Endocrinol (Oxf)       Date:  2015-01-09       Impact factor: 3.478

Review 5.  An update on the medical treatment of Graves' hyperthyroidism.

Authors:  Michele Marinò; Francesco Latrofa; Francesca Menconi; Luca Chiovato; Paolo Vitti
Journal:  J Endocrinol Invest       Date:  2014-09-04       Impact factor: 4.256

Review 6.  Autoimmune thyroid disorders.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Alda Corrado; Andrea Di Domenicantonio; Poupak Fallahi
Journal:  Autoimmun Rev       Date:  2014-10-25       Impact factor: 9.754

Review 7.  Future Prospects for the Treatment of Graves' Hyperthyroidism and Eye Disease.

Authors:  S Neumann; R F Place; C C Krieger; M C Gershengorn
Journal:  Horm Metab Res       Date:  2015-07-21       Impact factor: 2.936

8.  Predictors of long-term remission in patients with Graves' disease: a single center experience.

Authors:  Panagiotis Anagnostis; Fotini Adamidou; Stergios A Polyzos; Simoni Katergari; Eleni Karathanasi; Chrisanthi Zouli; Athanasios Panagiotou; Marina Kita
Journal:  Endocrine       Date:  2013-02-11       Impact factor: 3.633

9.  Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies.

Authors:  Demet Corapçioğlu; Vedia Tonyukuk; Mehmet Kiyan; Arif E Yilmaz; Rifat Emral; Nuri Kamel; Gürbüz Erdoğan
Journal:  Thyroid       Date:  2002-07       Impact factor: 6.568

10.  Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.

Authors:  Nieves Velez de Mendizabal; Matthew M Hutmacher; Iñaki F Troconiz; Joaquín Goñi; Pablo Villoslada; Francesca Bagnato; Robert R Bies
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

View more
  5 in total

1.  A journey from brain to muscle across the thyroid continent.

Authors:  Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

2.  Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Graves' Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method.

Authors:  Verena Theiler-Schwetz; Thomas Benninger; Christian Trummer; Stefan Pilz; Markus Reichhartinger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-31       Impact factor: 6.055

3.  A patient-specific treatment model for Graves' hyperthyroidism.

Authors:  Balamurugan Pandiyan; Stephen J Merrill; Flavia Di Bari; Alessandro Antonelli; Salvatore Benvenga
Journal:  Theor Biol Med Model       Date:  2018-01-09       Impact factor: 2.432

Review 4.  Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming.

Authors:  Apostolos Chatzitomaris; Rudolf Hoermann; John E Midgley; Steffen Hering; Aline Urban; Barbara Dietrich; Assjana Abood; Harald H Klein; Johannes W Dietrich
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-20       Impact factor: 5.555

5.  Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse.

Authors:  Jianhui Li; Xiaohua Sun; Danzhen Yao; Jinying Xia
Journal:  Int J Endocrinol       Date:  2018-03-11       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.